AcouSort AB (publ) (ACOU.ST)
SEK 4.04
(5.48%)
SEK 4.04
(5.48%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.38 Million SEK | 188.18% |
| 2022 | 2.91 Million SEK | 431.2% |
| 2021 | 548 Thousand SEK | -81.94% |
| 2020 | 3.03 Million SEK | 181.28% |
| 2019 | 1.07 Million SEK | 822.22% |
| 2018 | 117 Thousand SEK | -94.0% |
| 2017 | 1.95 Million SEK | 403.27% |
| 2016 | -643 Thousand SEK | -118.22% |
| 2015 | -294.65 Thousand SEK | -939.06% |
| 2014 | 35.11 Thousand SEK | 103.78% |
| 2013 | -929.45 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -5.7 Million SEK | 116.24% |
| 2024 Q1 | -5.91 Million SEK | -738.88% |
| 2023 Q2 | 1.63 Million SEK | -1.62% |
| 2023 Q4 | 926 Thousand SEK | 23.63% |
| 2023 FY | -22.5 Million SEK | -873.07% |
| 2023 Q3 | 749 Thousand SEK | -54.19% |
| 2023 Q1 | 1.66 Million SEK | -12.43% |
| 2022 FY | 2.91 Million SEK | 431.2% |
| 2022 Q4 | 1.89 Million SEK | 1229.76% |
| 2022 Q3 | -168 Thousand SEK | -370.97% |
| 2022 Q2 | 62 Thousand SEK | -94.45% |
| 2022 Q1 | 1.11 Million SEK | 535.02% |
| 2021 Q4 | -257 Thousand SEK | 28.81% |
| 2021 Q1 | 1.2 Million SEK | 162.75% |
| 2021 Q2 | -524 Thousand SEK | -143.45% |
| 2021 Q3 | -361 Thousand SEK | 31.11% |
| 2021 FY | 548 Thousand SEK | -81.94% |
| 2020 Q3 | -81 Thousand SEK | -110.25% |
| 2020 FY | 3.03 Million SEK | 181.28% |
| 2020 Q1 | 1.86 Million SEK | 726.11% |
| 2020 Q2 | 790 Thousand SEK | -57.69% |
| 2020 Q4 | 459 Thousand SEK | 666.67% |
| 2019 Q2 | -186 Thousand SEK | -125.14% |
| 2019 FY | 1.07 Million SEK | 822.22% |
| 2019 Q4 | 226 Thousand SEK | -24.67% |
| 2019 Q3 | 300 Thousand SEK | 261.29% |
| 2019 Q1 | 740 Thousand SEK | 188.62% |
| 2018 Q1 | 1000.00 SEK | -99.78% |
| 2018 Q4 | -835 Thousand SEK | -3379.17% |
| 2018 FY | 117 Thousand SEK | -94.0% |
| 2018 Q3 | -24 Thousand SEK | -102.72% |
| 2018 Q2 | 883 Thousand SEK | 88200.0% |
| 2017 Q3 | 531 Thousand SEK | -5.35% |
| 2017 FY | 1.95 Million SEK | 403.27% |
| 2017 Q1 | 393 Thousand SEK | 139.38% |
| 2017 Q2 | 561 Thousand SEK | 42.75% |
| 2017 Q4 | 465 Thousand SEK | -12.43% |
| 2016 Q3 | 462 Thousand SEK | 250.0% |
| 2016 FY | -643 Thousand SEK | -118.22% |
| 2016 Q1 | -148 Thousand SEK | 53.11% |
| 2016 Q4 | -998 Thousand SEK | -316.02% |
| 2016 Q2 | 132 Thousand SEK | 189.19% |
| 2015 Q4 | -315.65 Thousand SEK | -188.42% |
| 2015 Q3 | 357 Thousand SEK | 0.0% |
| 2015 FY | -294.65 Thousand SEK | -939.06% |
| 2014 FY | 35.11 Thousand SEK | 103.78% |
| 2013 FY | -929.45 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Active Biotech AB (publ) | -1.67 Million SEK | 600.836% |
| Biovica International AB (publ) | 6.87 Million SEK | -21.986% |
| Cantargia AB (publ) | -3.45 Million SEK | 343.089% |
| CombiGene AB (publ) | -21.29 Million SEK | 139.402% |
| Cyxone AB (publ) | 2.61 Million SEK | -221.295% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -167.763% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 25.22% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -146.518% |
| Fluicell AB (publ) | 1.73 Million SEK | -382.681% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -10794.805% |
| Mendus AB (publ) | 28.48 Million SEK | 70.551% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 124.376% |
| I-Tech AB | 27.56 Million SEK | 69.568% |
| Intervacc AB (publ) | -13.79 Million SEK | 160.816% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 263.944% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 15.798% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | 3000.00 SEK | -279533.333% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 79.924% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 76.294% |
| Lipum AB (publ) | 53 Thousand SEK | -15728.302% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 105.221% |
| Ziccum AB (publ) | -23.28 Million SEK | 136.026% |
| BioArctic AB (publ) | 346.31 Million SEK | 97.578% |
| Genovis AB (publ.) | 54 Million SEK | 84.465% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.469% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 106.835% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 68.722% |
| Aptahem AB (publ) | 2.63 Million SEK | -218.895% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 345.221% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 191.244% |
| Kancera AB (publ) | -1.96 Million SEK | 526.921% |
| Saniona AB (publ) | 11.78 Million SEK | 28.792% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 136.031% |
| Xintela AB (publ) | 78 Thousand SEK | -10655.128% |
| Abliva AB (publ) | -35.66 Million SEK | 123.523% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -198.86% |
| Amniotics AB (publ) | -1.93 Million SEK | 534.663% |
| 2cureX AB (publ) | -37.48 Million SEK | 122.378% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 2083.215% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.257% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 88.176% |
| Biosergen AB | -456 Thousand SEK | 1939.693% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -286.412% |
| Corline Biomedical AB | 28.38 Million SEK | 70.44% |
| NextCell Pharma AB | -43.74 Million SEK | 119.176% |
| Nanologica AB (publ) | -76 Thousand SEK | 11138.158% |
| LIDDS AB (publ) | -12.92 Million SEK | 164.92% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 105.711% |
| BioInvent International AB (publ) | 71.46 Million SEK | 88.261% |
| SynAct Pharma AB | -778 Thousand SEK | 1178.278% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 4446.632% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 57.789% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 899.714% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 76.889% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -473.403% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 56026.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -405.971% |
| Simris Alg AB (publ) | 2 Million SEK | -317.987% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 334.33% |